Rimegepant for Preventing Migraine in Children and Adolescents
This study is testing a medication called rimegepant (75mg or 50mg ODT) to see if it can help prevent migraines in children and adolescents aged 6 to 17 years. Researchers want to compare rimegepant to a placebo (an inactive substance) to understand how well it works and if it's safe. You might be able to join if you have a history of migraine, typically have 14 or fewer headache days per month, and experience at least 6 migraine days during a specific observation period. The main goal is to see if rimegepant reduces the average number of migraine days per month over 12 weeks. This study plans to enroll 640 participants, but its current status is unclear.
- Study design
- This is an interventional study comparing rimegepant to a placebo. It is designed to enroll 640 participants aged 6 to 17 years.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary endpoint is measured at 3 months (12 weeks).
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects
At a glance
Conditions
Where it's being run
93 sites across 53 statesStudy leadership
- Pfizer CT.gov Call Center · STUDY_DIRECTOR · Pfizer
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Change from baseline in the mean number of migraine days per month as measured over the 12-week double-blind phase of the study in adolescents with episodic migraine3 months (12 weeks)
Reduction from baseline in mean number of migraine days per month